ELOVL7 Antibody
| Code | Size | Price |
|---|
| PSI-5641-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5641-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
ELOVL7 Antibody: Elongation of very long chain fatty acids protein 7, 3-keto acyl-CoA synthase ELOVL7, ELOVL FA elongase 7
Application Note:
ELOVL7 antibody can be used for detection of ELOVL7 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
ELOVL7 Antibody: Lipogenesis is a key event in the energy storage system and is controlled by the transcription factor sterol regulatory element-binding protein (SREBP)-1. Elongation of very long chain fatty acids protein 7 (ELOVL7) is a member of fatty acyl-CoA elongase gene family that elongates saturated very-long-chain fatty acids (SVLFA, C20:0-) and has been suggested to be involved in prostate cancer growth through saturated long-chain fatty acid metabolism. The metabolic pathways of long-chain fatty acids play an important role in the maintenance of membrane lipid composition and the generation of cell signaling precursor molecules such as eicosanoids and sphingosine-1 phosphate. Overexpression of ELOVL7 results in lipid accumulation in differentiated adipocytes; its expression is regulated by the microRNA miR-219.
Background References:
- Tamura K, Makino A, Hullin-Matsuda F, et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res.2009; 69:8133-40.
- Leonard AE, Pereira SL, Sprecher H, et al. Elongation of long-chain fatty acids. Prog. Lipid Res.2004; 43:36-54.
- Shin D, Shin JY, McManus MT, et al. Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann. Neurol.2009; 66:843-57.
Buffer:
ELOVL7 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (100%), Bovine: (100%)
Immunogen:
ELOVL7 antibody was raised against a 15 amino acid synthetic peptide near the amino terminus of human ELOVL7.
The immunogen is located within amino acids 40 - 90 of ELOVL7.
The immunogen is located within amino acids 40 - 90 of ELOVL7.
NCBI Gene ID #:
79993
NCBI Official Name:
ELOVL family member 7, elongation of long chain fatty acids (yeast)
NCBI Official Symbol:
ELOVL7
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_001098028
Protein GI Number:
157388949
Purification:
ELOVL7 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
Swissprot #:
A1L3X0
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | ELOVL7 Peptide | PSI-5641P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|